Based on the impact that EBV reactivation appeared to have on IgM+ MBC, we further assessed if the abundance of CXCR3+ IgM+ MBCs was increased as previously observed (14) and could confirm a significantly increased proportion of CXCR3+ IgM+ MBC in VCA IgM Ab+ individuals compared to VCA IgM Ab- CIS/MS patients or controls (Figure 7I). The gene discussed is CXCR3; the disease is in situ carcinoma.